Smith Ernest S. 4

4 · VACCINEX, INC. · Filed Mar 22, 2024

Form 4

Period: 2024-03-20

SVP, Research & CSO

Transactions

Award
Stock Option (Right to Buy)
2024-03-20+1,341→ 1,341 total
Exercise: $8.32Exp: 2034-03-20→ Common Stock (1,341 underlying)

Holdings

Stock Option (Right to Buy)
Exercise: $83.90Exp: 2033-03-30→ Common Stock (190 underlying)
190
Stock Option (Right to Buy)
Exercise: $1491.00Exp: 2025-12-22→ Common Stock (193 underlying)
193
Stock Option (Right to Buy)
Exercise: $819.00Exp: 2029-03-14→ Common Stock (38 underlying)
38
Stock Option (Right to Buy)
Exercise: $615.30Exp: 2031-04-02→ Common Stock (47 underlying)
47
Common Stock
39
Stock Option (Right to Buy)
Exercise: $1491.00Exp: 2025-12-23→ Common Stock (24 underlying)
24
Stock Option (Right to Buy)
Exercise: $270.90Exp: 2032-04-01→ Common Stock (95 underlying)
95
Stock Option (Right to Buy)
Exercise: $1274.70Exp: 2030-02-24→ Common Stock (38 underlying)
38

Footnotes (5)

[F1]Exercisable in full as of the date of this report.
[F2]This option vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date, except as otherwise provided in the award notice.
[F3]This option vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date, except as otherwise provided in the award notice.
[F4]This option vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date, except as otherwise provided in the award notice.
[F5]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 20, 2024 grant date.

Documents

1 file